Efficient transduction of human hematopoietic repopulating cells with a chimeric HIV1-based vector including SIV capsid

Experimental Hematology

Volumn 41, Issue 9, 2013, Pages 779-788.e1

  Uchida, Naoya ^a   Hsieh, Matthew M ^a   Washington, Kareem N ^a,b   Tisdale, John F ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CD34 ANTIGEN; CHIMERIC HUMAN IMMUNODEFICIENCY VIRUS 1 VECTOR CONTAINING SIMIAN IMMUNODEFICIENCY VIRUS CAPSID PROTEIN; CYCLOPHILIN A; CYCLOSPORIN; HUMAN IMMUNODEFICIENCY VIRUS 1 VECTOR; LENTIVIRUS VECTOR; TRIPARTITE MOTIF PROTEIN 5; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL POPULATION; CELL TRANSPLANTATION; CELL VIABILITY; COLONY FORMING UNIT; COMPARATIVE STUDY; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; GENE EXPRESSION; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; HEMATOPOIETIC CELL; HEMATOPOIETIC REPOPULATING CELL; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNE EVASION; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; MALE; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSDUCTION EFFICIENCY; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; XENOGRAFT;

MIRIDAE; MUS; PRIMATES; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 84883556680     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2013.04.014     Document Type: Article

References (33)

1. Aiuti A., Cattaneo F., Galimberti S., et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 2009, 360:447-458.
2. Aiuti A., Slavin S., Aker M., et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002, 296:2410-2413.
3. Hacein-Bey-Abina S., Garrigue A., Wang G.P., et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008, 118:3132-3142.
4. Hacein-Bey-Abina S., von Kalle C., Schmidt M., et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003, 348:255-256.
5. Schwarzwaelder K., Howe S.J., Schmidt M., et al. Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution invivo. J Clin Invest 2007, 117:2241-2249.
6. Ott M.G., Schmidt M., Schwarzwaelder K., et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006, 12:401-409.
7. Cavazzana-Calvo M., Payen E., Negre O., et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 2010, 467:318-322.
8. Wissing S., Galloway N.L., Greene W.C. HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors. Mol Aspects Med 2010, 31:383-397.
9. Nakayama E.E., Shioda T. Anti-retroviral activity of TRIM5 alpha. Rev Med Virol 2010, 20:77-92.
10. Luban J. Cyclophilin A, TRIM5, and resistance to human immunodeficiency virus type 1 infection. J Virol 2007, 81:1054-1061.
11. Sakuma R., Noser J.A., Ohmine S., Ikeda Y. Inhibition of HIV-1 replication by simian restriction factors, TRIM5alpha and APOBEC3G. Gene Ther 2007, 14:185-189.
12. Stremlau M., Owens C.M., Perron M.J., Kiessling M., Autissier P., Sodroski J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 2004, 427:848-853.
13. Keckesova Z., Ylinen L.M., Towers G.J. The human and African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction factor activities. Proc Natl Acad Sci U S A 2004, 101:10780-10785.
14. Hatziioannou T., Perez-Caballero D., Yang A., Cowan S., Bieniasz P.D. Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha. Proc Natl Acad Sci U S A 2004, 101:10774-10779.
15. Yap M.W., Nisole S., Lynch C., Stoye J.P. Trim5alpha protein restricts both HIV-1 and murine leukemia virus. Proc Natl Acad Sci U S A 2004, 101:10786-10791.
16. Uchida N., Washington K.N., Hayakawa J., et al. Development of a human immunodeficiency virus type 1-based lentiviral vector that allows efficient transduction of both human and rhesus blood cells. J Virol 2009, 83:9854-9862.
17. Uchida N., Hsieh M.M., Hayakawa J., Madison C., Washington K.N., Tisdale J.F. Optimal conditions for lentiviral transduction of engrafting human CD34+ cells. Gene Ther 2011, 18:1078-1086.
18. Uchida N., Washington K.N., Lap C.J., Hsieh M.M., Tisdale J.F. Chicken HS4 insulators have minimal barrier function among progeny of human hematopoietic cells transduced with an HIV1-based lentiviral vector. Mol Ther 2011, 19:133-139.
19. Uchida N., Bonifacino A., Krouse A.E., et al. Accelerated lymphocyte reconstitution and long-term recovery after transplantation of lentiviral-transduced rhesus CD34(+) cells mobilized by G-CSF and plerixafor. Exp Hematol 2011, 39:795-805.
20. Hanawa H., Persons D.A., Nienhuis A.W. Mobilization and mechanism of transcription of integrated self-inactivating lentiviral vectors. J Virol 2005, 79:8410-8421.
21. Hanawa H., Kelly P.F., Nathwani A.C., et al. Comparison of various envelope proteins for their ability to pseudotype lentiviral vectors and transduce primitive hematopoietic cells from human blood. Mol Ther 2002, 5:242-251.
22. Hanawa H., Hematti P., Keyvanfar K., et al. Efficient gene transfer into rhesus repopulating hematopoietic stem cells using a simian immunodeficiency virus-based lentiviral vector system. Blood 2004, 103:4062-4069.
23. Uchida N., Hanawa H., Dan K., Inokuchi K., Shimada T. Leukemogenesis of b2a2-type p210 BCR/ABL in a bone marrow transplantation mouse model using a lentiviral vector. J Nippon Med Sch 2009, 76:134-147.
24. Hayakawa J., Hsieh M.M., Anderson D.E., et al. The assessment of human erythroid output in NOD/SCID mice reconstituted with human hematopoietic stem cells. Cell Transplant 2010, 19:1465-1473.
25. Tisdale J.F., Hanazono Y., Sellers S.E., et al. Exvivo expansion of genetically marked rhesus peripheral blood progenitor cells results in diminished long-term repopulating ability. Blood 1998, 92:1131-1141.
26. Palombella V.J., Rando O.J., Goldberg A.L., Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 1994, 78:773-785.
27. Sutlu T., Nystrom S., Gilljam M., Stellan B., Applequist S.E., Alici E. Inhibition of intracellular antiviral defense mechanisms augments lentiviral transduction of human natural killer cells: implications for gene therapy. Hum Gene Ther 2012, 23:1090-1100.
28. Santoni de Sio F.R., Gritti A., Cascio P., et al. Lentiviral vector gene transfer is limited by the proteasome at postentry steps in various types of stem cells. Stem Cells 2008, 26:2142-2152.
29. Meriin A.B., Gabai V.L., Yaglom J., Shifrin V.I., Sherman M.Y. Proteasome inhibitors activate stress kinases and induce Hsp72. Diverse effects on apoptosis. J Biol Chem 1998, 273:6373-6379.
30. Schwartz O., Marechal V., Friguet B., Arenzana-Seisdedos F., Heard J.M. Antiviral activity of the proteasome on incoming human immunodeficiency virus type 1. J Virol 1998, 72:3845-3850.
31. Drexler H.C. Activation of the cell death program by inhibition ofproteasome function. Proc Natl Acad Sci U S A 1997, 94:855-860.
32. Grimm L.M., Goldberg A.L., Poirier G.G., Schwartz L.M., Osborne B.A. Proteasomes play an essential role in thymocyte apoptosis. EMBO J 1996, 15:3835-3844.
33. Uchida N., Hargrove P.W., Lap C.J., et al. High-efficiency transduction of rhesus hematopoietic repopulating cells by a modified HIV1-based lentiviral vector. Mol Ther 2012, 20:1882-1892.